SUMO1 and cardiac hypertrophy: Studies have also shown that cardiomyocyte‐specific overexpression of SUMO‐1 with AAV9 reduced the cardiac hypertrophy phenotype.65, 66 Targeting SERCA2a with adeno‐associated vector type 1 encoding SERCA2a (AAV1.SERCA2a) is considered as a new therapeutic target to treat heart failure.67 The initial Phase II of the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trials delivering the SERCA2a gene for treatment of heart failure has shown potential clinical benefits.